9th Mayo Clinic Symposium on lmmuno-Oncology and Tumor Microenvironment Crosstalk 2022 Livestream
December 9-11, 2022 - Livestream
Mayo Clinic's 9th Annual Symposium on lmmuno-Oncology and Tumor Microenvironment Crosstalk at the Omni Amelia Island Resort in Fernandina Beach, Florida brings together basic scientists, clinical experts and industry partners in the field of tumor microenvironment, immune therapy, anti-angiogenesis and targeted therapy. This symposium will facilitate the exchange of ideas and new scientific direction involving basic biology and pathways that eventually lead to new individualize therapy for patients. Clinician scientists will present the results of ongoing clinical trials on targeted therapy including immune therapy, anti-angiogenic therapy and others. Novel genetic and imaging methods to assess alteration of tumor microenvironment for monitoring the effectiveness of therapeutic responses in both pre-clinical and clinical trials will be discussed. Different clinical challenges and benefits of new therapeutic avenues including cardio-oncology will be presented. Overall, it is hoped that this symposium will assist in establishing strong collaborations among leading national, international, and Mayo Clinic experts in the field.
This course is designed for basic scientists, oncology specialists and vascular specialists.
Upon completion of this activity, participants should be able to:
- Assess the role of microenvironment and immune crosstalk in different pathological situations.
- Analyze the molecular pathways in vascular biology, immunology and stromal compartments in different indications including cancer.
- Identify the importance of angiogenesis in cancer progression and metastasis.
- Evaluate novel targets that can overcome therapy resistances as a potential target for future cancer therapy.
- Identify the therapeutic potential of anti-stromal molecules and translate basic science to clinical applications.
- Review novel technologies related to nanotechnology and synthetic biology.
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Prioritizing and addressing diversity, equity and inclusion in workforce development and organizational culture is essential to providing optimal patient care, achieving health equity, and attracting and engaging the workforce of the future. The course brings together a diverse mix of scientists, clinical experts, students, and industry partners in the field of tumor microenvironment, immune therapy, anti-angiogenesis and targeted therapy.
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Mayo Clinic College of Medicine and Science designates this other activity (live and livestream) for a maximum of 18.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Osteopathic Association designates this program for a maximum of 18.25 AOA Category 2-A credits.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
- 18.25 AMA PRA Category 1 Credit™
- 18.25 AOA Category 2-A
- 18.25 Attendance